NCT05585034 2025-08-07Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid TumorsXencor, Inc.Phase 1 Completed60 enrolled
NCT02606305 2024-06-14Study of Mirvetuximab Soravtansine in Combination With Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab, or Bevacizumab + Carboplatin in Participants With Folate Receptor Alpha (FRα) Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal, or Fallopian Tube CancerImmunoGen, Inc.Phase 1/2 Completed264 enrolled 41 charts
NCT04148937 2024-04-05A Study of the CD73 Inhibitor LY3475070 Alone or in Combination With Pembrolizumab in Participants With Advanced CancerEli Lilly and CompanyPhase 1 Completed52 enrolled 21 charts
NCT02728830 2024-02-21A Study of Pembrolizumab on the Tumoral Immunoprofile of Gynecologic CancersDuke UniversityPhase EARLY_PHASE1 Completed39 enrolled 16 charts